Signaling

Results of BETonMACE with Kausik Ray, MD, FAHA

Kausik Ray, MD, FAHA explains whether treatment with apabetalone compared to standard of care therapies improves CV outcomes in patients with T2DM and low HDL-C after an acute coronary syndrome (ACS). Dr. Ray is a deputy director of Imperial College London's Clinical Trials Unit. See this study and other late-breaking science presentations on our AHA Science News page.

Science News

2020 AHA/ACC Consensus Conference on Professionalism and Ethics
Sex-Specific Control of Human Heart Maturation by the Progesterone Receptor
Extracellular Vesicles from Epicardial Fat Facilitate Atrial Fibrillation
The Association of Serum Aldosterone and Plasma Renin Activity with Ambulatory Blood Pressure in African Americans: The Jackson Heart Study
MicroRNA Biophysically Modulates Cardiac Action Potential via Directly Binding to Ion Channel

Journals

Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans
Ischemia From Nonculprit Stenoses Is Not Associated With Reduced Culprit Infarct Size in Patients with ST-Segment–Elevation Myocardial Infarction
FXYD1 Is Protective Against Vascular Dysfunction
CAPN1 (Calpain1)-Mediated Impairment of Autophagic Flux Contributes to Cerebral Ischemia-Induced Neuronal Damage
Loss of Transforming Growth Factor Beta Signaling in Aortic Smooth Muscle Cells Causes Endothelial Dysfunction and Aortic Hypercontractility

Continuing Education

The incentive to disseminate the latest cardiovascular and stroke science to colleagues around the world has never been greater.

Clinicians and Scientists thrive on collaboration and sharing their study findings. Present your innovative research to a global audience at Scientific Sessions, the world's premier cardiovascular conference.

We know your work is vital to saving lives. Share it with fellow researchers, clinicians, and scientists.

The ATVB Council focuses on arteriosclerosis, thrombosis and vascular biology. The council advances research, addresses prevention, improves diagnosis and treatment, and works actively with other organizations. It shares reliable information through its annual conference, awards and lectures, and in the AHA’s journal, Arteriosclerosis, Thrombosis, and Vascular Biology.


Since 1999, the BCVS Council has advanced understanding of mechanisms of basic cardiovascular regulation to support insights into cardiovascular disease and facilitate new therapies. Emphasis is on integrating molecular/cellular and physiological approaches to address problems relating to genomics, cell signaling, myocardial biology, circulatory physiology, pathophysiology, and peripheral vascular disease.


The GPM Council seeks to advance discovery and translation of biological insights from genetics and omics technologies to improve cardiovascular and brain health through better risk prediction, treatment and prevention for patients. Our expertise spans genetics, genomics, genomic medicine, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, and population health.


PVD Council members are focused on improving the care of patients with vascular diseases by advancing science, education, advocacy, and improved healthcare delivery. Members support the AHA mission through active involvement in the council’s scientific initiatives and educational programs, including the annual Scientific Sessions and Vascular Discovery meetings.


American Heart Association Professional Members

Enjoy instant benefits!

  • Free Online Access to AHA Scientific Journals
  • Affiliate with our 16 Scientific Councils
  • Discounts on Scientific Conference Registration and Online Courses